

CYDAN SCHOLARSHIP FOR RARE DISEASES

FAQs

What is Cydan?

[Cydan Development](#) is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan focuses on selecting promising programs with well-understood biology from academia, industry and other sources. Data generated during a rigorous de-risking process enables formation of stand-alone companies and strategic partnerships.

What is the exact criteria of this scholarship?

The startup or startups must be working within these fields:

- Therapeutics for rare disorders
- Translational - Pre-IND therapeutic approaches
- Focus on monogenic diseases
- Agnostic to therapeutic modality - small molecules, peptides, proteins, antibodies, AAV gene therapy, sRNA, etc.
- Secondly approaches to expedite rare disease diagnosis or support tools to assist patients with rare disorders
- Technology that supports and improves the quality of life of patients with rare disorders

I'm still confused! Can you help?

Of course! Please e-mail apply@masschallenge.org and we'll be happy to answer any questions you may have.